Ask AI
ProCE Banner Activity

PARP Inhibitors for Prostate Cancer: Expert Answers to Your Questions

Clinical Thought

Daniel P. Petrylak, MD, answers healthcare professionals’ questions on leveraging PARP inhibitor–based therapies for prostate cancer, including gene differences in sensitivity to PARP inhibition, when to repeat somatic testing, and how to choose between approved PARP inhibitor combination regimens.

Released: April 09, 2024

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.

AstraZeneca

Merck & Co., Inc., Rahway, NJ, USA

Faculty Disclosure

Primary Author

Daniel P. Petrylak, MD

Professor of Medicine and Urology
Director, Genitourinary Oncology Research Program
Co-Director, Signal Transduction Program
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, Connecticut

Daniel P. Petrylak, MD: consultant/advisor/speaker: Ada Cap, Amgen, Astellas, AstraZeneca, Bayer, Bicycle, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly, Exelixis, Gilead, Incyte, Infinity, Ipsen, Janssen, Merck, Mirati, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Sanofi-Aventis, Seattle Genetics, Urogen; researcher: Ada Cap, Agensys, Arvians, Astellas, AstraZeneca, Bayer, BioXcel, Bristol Myers Squibb, Clovis Oncology, Daiichi Sankyo, Eisai, Endocyte, Ferring, Genentech, Gilead, Innocrin, Lilly, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi-Aventis, Seattle Genetics.